Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

CBIO

Crescent Biopharma Inc

Dec 08 • 04:00PM ET

13.17

+0.10 0.77 %

Healthcare • Biotechnology • USA • NASD

Peers: FATE AXSM AFMD HOOK IMMP XFOR CDTX NERV PVLA SYBX

| Held by: VTI VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-21.97	Insider Own	22.62%	Shs Outstand	13.89M	Perf Week	-7.71%
Market Cap	182.97M	Forward P/E	-	EPS next Y	-5.83	Insider Trans	76.29%	Shs Float	10.75M	Perf Month	0.53%
Enterprise Value	55.45M	PEG	-	EPS next Q	-2.44	Inst Own	69.67%	Short Float	5.40%	Perf Quarter	4.94%
Income	-55.96M	P/S	-	EPS this Y	78.89%	Inst Trans	-3.98%	Short Ratio	4.16	Perf Half Y	-25.42%
Sales	0.00M	P/B	1.62	EPS next Y	53.23%	ROA	-72.70%	Short Interest	0.58M	Perf YTD	-47.11%
Book/sh	8.11	P/C	1.37	EPS next 5Y	58.55%	ROE	-87.43%	52W High	37.00 -64.41%	Perf Year	-56.25%
Cash/sh	9.59	P/FCF	-	EPS past 3/5Y	21.89% 15.18%	ROIC	-47.44%	52W Low	9.81 34.25%	Perf 3Y	-93.85%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	13.58% 6.67%	Perf 5Y	-96.49%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	64.36%	Oper. Margin	-	ATR (14)	1.00	Perf 10Y	-98.11%
Dividend Ex-Date	-	Quick Ratio	6.63	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	48.81	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	6.63	EPS Q/Q	90.23%	SMA20	-2.02%	Beta	1.33	Target Price	28.20
Payout	-	Debt/Eq	0.01	Sales Q/Q	-	SMA50	3.84%	Rel Volume	0.96	Prev Close	13.07
Employees	26	LT Debt/Eq	0.01	Earnings	Nov 06 BMO	SMA200	-23.62%	Avg Volume	139.79K	Price	13.17
IPO	Jan 10, 2014	Option/Short	No / Yes	EPS/Sales Surpr.	35.17% -	Trades		Volume	134,050	Change	0.77%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-25-25	Initiated	Jefferies	Buy	$26
Aug-11-25	Initiated	H.C. Wainwright	Buy	$25
Jul-14-25	Initiated	Wedbush	Outperform	$27
Jun-25-25	Initiated	Stifel	Buy	$28
Mar-21-25	Initiated	Cantor Fitzgerald	Overweight
Jul-26-24	Downgrade	TD Cowen	Buy → Hold
Dec-22-23	Initiated	CapitalOne	Overweight	$12
Nov-12-21	Upgrade	Jefferies	Hold → Buy	$3 → $4
Nov-14-19	Initiated	ROTH Capital	Buy	$12
Aug-05-19	Downgrade	SunTrust	Buy → Hold	$23 → $5
Aug-05-19	Downgrade	Piper Jaffray	Overweight → Neutral	$20 → $6
Aug-05-19	Downgrade	Jefferies	Buy → Hold
Apr-12-19	Initiated	Piper Jaffray	Overweight	$20
Dec-18-18	Initiated	H.C. Wainwright	Buy	$24
Jul-26-16	Initiated	SunTrust	Buy
Mar-17-15	Reiterated	Stifel	Buy	$13 → $14

Show Previous Ratings

Dec-05-25 09:36AM	Crescent and Kelun-Biotech swap cancer asset rights in double deal (Pharmaceutical Technology)
05:00AM	Praxis soars higher; Bristol Myers CAR-T therapy wins broader use (BioPharma Dive)
Dec-04-25 06:35AM	Crescent Biopharma Announces Transformational Partnership with Kelun-Biotech and $185 Million Private Placement, Accelerating and Expanding Global Pipeline of Next Generation Therapeutics for Solid Tumors (GlobeNewswire)
06:30AM	Kelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology Therapeutics (GlobeNewswire)
Nov-17-25 04:15PM	Crescent Biopharma Announces Grants of Inducement Awards (GlobeNewswire)
07:40AM	Loading…
Nov-06-25 07:40AM	Crescent Biopharma: Q3 Earnings Snapshot (Associated Press Finance) +5.39%
07:30AM	Crescent Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
Nov-05-25 07:30AM	Crescent Biopharma to Present at November Investor Conferences (GlobeNewswire)
Nov-04-25 09:05AM	Crescent Biopharma to Present Preclinical Data for CR-001, a PD-1 x VEGF Bispecific Antibody, at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting (GlobeNewswire)
Aug-28-25 07:30AM	Crescent Biopharma to Present at September Investor Conferences (GlobeNewswire)
Jul-31-25 07:34AM	Crescent Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
07:32AM	Crescent Biopharma: Q2 Earnings Snapshot (Associated Press Finance)
Jul-08-25 07:30AM	Crescent Biopharma Appoints Jan Pinkas, Ph.D., as Chief Scientific Officer (GlobeNewswire)
Jun-05-25 04:01PM	GlycoMimetics Stockholders Approve Proposed Merger with Crescent Biopharma and All Related Proposals (Business Wire) -5.43%
May-14-25 07:02PM	GlycoMimetics: Q1 Earnings Snapshot (Associated Press Finance) -5.50%
07:30AM	Loading…
Apr-28-25 07:30AM	Crescent Biopharma Appoints David Lubner to Board of Directors (GlobeNewswire)
Apr-03-25 07:30AM	Crescent Biopharma Appoints Joshua Brumm as Chief Executive Officer and Expands Leadership Team to Advance Pipeline of Potentially Best-in-Class Oncology Therapeutics (GlobeNewswire) -11.73%
Jan-14-25 09:34AM	GlycoMimetics and Crescent Biopharma Announce Merger Plans (TipRanks)
Nov-13-24 05:15PM	GlycoMimetics: Q3 Earnings Snapshot (Associated Press Finance)
Nov-12-24 08:00AM	Crescent Biopharma to Present at Jefferies London Healthcare Conference 2024 (PR Newswire) -5.29%
Nov-06-24 07:00AM	GlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual Meeting (Business Wire)
Oct-30-24 08:31AM	GlycoMimetics Announces Merger with Crescent Biopharma (TipRanks) -6.84%
Oct-29-24 07:00AM	GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma (Business Wire) +191.32%
06:30AM	GlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint (Business Wire)
Jul-25-24 09:00AM	GlycoMimetics Announces Strategic Review and Corporate Restructuring Plan (Business Wire) -24.20%
Jul-22-24 07:00AM	7 Sorry Biotech Stocks Set to Make Investors Sad (InvestorPlace) +13.89%
Jun-26-24 07:41AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace) -12.60%
Jun-25-24 07:37AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace) +25.28%
Jun-04-24 07:00AM	GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) (Business Wire) +7.38%
May-29-24 04:01PM	GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024 (Business Wire) +6.82%
04:05AM	Loading…
May-28-24 04:05AM	Pipeline Moves: Phase III AML trial fails to meet primary endpoint (Clinical Trials Arena)
May-09-24 10:58PM	GLYC Stock Earnings: GlycoMimetics Misses EPS for Q1 2024 (InvestorPlace) -10.54%
07:19PM	GlycoMimetics: Q1 Earnings Snapshot (Associated Press Finance)
May-08-24 07:42AM	Uproleselans failed Phase III AML trial shakes up GlycoMimetics future (Clinical Trials Arena)
May-07-24 05:21AM	GlycoMimetics reports data from Phase III AML treatment trial (Clinical Trials Arena)
May-06-24 03:53PM	Sector Update: Health Care Stocks Higher in Late Afternoon Trading (MT Newswires) -82.76%
12:45PM	GlycoMimetics Shares Slump After Cancer Treatment Drug Combination Fails to Meet Primary Endpoint (MT Newswires)
08:40AM	Why Is GlycoMimetics (GLYC) Stock Down 77% Today? (InvestorPlace)
07:52AM	GlycoMimetics fails phase 3 blood cancer trial, causing investors to sour on stock (FierceBiotech.com)
07:28AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
06:00AM	GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) (Business Wire)
Apr-25-24 07:00AM	GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024 (Business Wire) -7.82%
Mar-28-24 10:12AM	GlycoMimetics, Inc. (NASDAQ:GLYC) Q4 2023 Earnings Call Transcript (Insider Monkey) -5.66%
02:10AM	Q4 2023 GlycoMimetics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-27-24 11:53AM	GLYC Stock Earnings: GlycoMimetics Beats EPS for Q4 2023 (InvestorPlace) +11.58%
10:31AM	GlycoMimetics Inc (GLYC) Posts Quarterly Loss, Aligns with Analyst Projections (GuruFocus.com)
07:14AM	GlycoMimetics: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023 (Business Wire)
Mar-21-24 08:50AM	Should You Buy GlycoMimetics (GLYC) Ahead of Earnings? (Zacks) -5.57%
Mar-13-24 07:00AM	GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024 (Business Wire)
Feb-26-24 07:00AM	GlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care Conference (Business Wire) +5.52%
Feb-12-24 07:00AM	GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (Business Wire) -5.47%
Jan-04-24 07:00AM	GlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687 (Business Wire)
Jan-03-24 07:00AM	Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia (GlobeNewswire) +11.40%
Dec-10-23 12:00PM	GlycoMimetics Announces Independent Presentations on Uproleselan at American Society of Hematology Annual Meeting including New Clinical Data in Treated Secondary Acute Myeloid Leukemia (Business Wire)
Nov-09-23 07:00AM	GlycoMimetics to Participate in Upcoming Jefferies London Healthcare Conference (Business Wire) -10.45%
Nov-05-23 08:51AM	GlycoMimetics, Inc. (NASDAQ:GLYC) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-04-23 01:48AM	Q3 2023 GlycoMimetics Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-03-23 10:33AM	GlycoMimetics Inc (GLYC) Reports Q3 2023 Financial Results (GuruFocus.com)
07:07AM	GlycoMimetics: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023 (Business Wire)
Oct-23-23 08:30AM	Anixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark A. Goldberg, to Cancer Business Advisory Board (PR Newswire) -7.14%
Oct-20-23 07:00AM	GlycoMimetics to Report Third Quarter 2023 Financial Results on November 3, 2023 (Business Wire)
Sep-06-23 07:00AM	GlycoMimetics Announces First Cohort Dosed in Human Phase 1a Study of GMI-1687 (Business Wire)
Sep-05-23 07:00AM	GlycoMimetics to Participate in Upcoming H.C. Wainwright 25th Annual Global Investment Conference (Business Wire) -5.10%
Aug-17-23 07:00AM	GlycoMimetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-02-23 07:17AM	GlycoMimetics: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2023 (Business Wire)
Jul-19-23 07:00AM	GlycoMimetics to Report Second Quarter 2023 Financial Results on August 2, 2023 (Business Wire) -6.43%
Jul-13-23 09:29AM	12 Best Multibagger Penny Stocks To Buy (Insider Monkey)
Jun-26-23 08:00AM	GlycoMimetics Announces Its Addition to the Russell Microcap® Index (Business Wire)
Jun-15-23 08:00AM	GlycoMimetics Announces U.S. Food and Drug Administration Clears Addition of Time-based Final Analysis to Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory Acute Myeloid Leukemia (Business Wire) +8.52%
Jun-12-23 11:13AM	We Think GlycoMimetics (NASDAQ:GLYC) Needs To Drive Business Growth Carefully (Simply Wall St.)
May-31-23 07:00AM	GlycoMimetics to Participate in Upcoming Jefferies 2023 Healthcare Conference (Business Wire)
May-16-23 10:37AM	retail investors who own 36% along with institutions invested in GlycoMimetics, Inc. (NASDAQ:GLYC) saw increase in their holdings value last week (Simply Wall St.) -6.73%
May-03-23 10:17PM	Q1 2023 GlycoMimetics Inc Earnings Call (Thomson Reuters StreetEvents) +7.35%
07:23AM	GlycoMimetics: Q1 Earnings Snapshot (AP Finance)
07:00AM	GlycoMimetics Reports Highlights and Financial Results for First Quarter 2023 (Business Wire)
Apr-26-23 07:00AM	GlycoMimetics to Report First Quarter 2023 Financial Results on May 3, 2023 (Business Wire)
Apr-19-23 10:20AM	Possible turnaround for GlycoMimetics, Inc. (NASDAQ:GLYC) insiders, still down US$63k after a US$732k shopping spree (Simply Wall St.)
Apr-05-23 01:45PM	The Quant Trading System Picking Stocks That Soar 300% (InvestorPlace)
Mar-31-23 04:30AM	GlycoMimetics, Inc. (NASDAQ:GLYC) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-29-23 07:00AM	GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Year-end 2022 (Business Wire) -9.29%
Mar-21-23 06:23AM	Daily Vickers Top Insider Picks for 03/21/2023 (Argus Research)
Mar-20-23 06:35AM	Daily Vickers Top Insider Picks for 03/20/2023 (Argus Research)
Mar-17-23 06:47AM	Daily Vickers Top Insider Picks for 03/17/2023 (Argus Research) -5.41%
Mar-16-23 07:00AM	GlycoMimetics to Report Fourth Quarter and 2022 Full Year Financial Results on March 29, 2023 (Business Wire)
06:51AM	Daily Vickers Top Insider Picks for 03/16/2023 (Argus Research)
Mar-15-23 06:44AM	Daily Vickers Top Insider Picks for 03/15/2023 (Argus Research)
Mar-13-23 06:32AM	Daily Vickers Top Insider Picks for 03/13/2023 (Argus Research) +10.69%
Mar-10-23 07:04AM	Daily Vickers Top Insider Picks for 03/10/2023 (Argus Research)
Mar-09-23 06:33AM	Daily Vickers Top Insider Picks for 03/09/2023 (Argus Research) -9.52%
Mar-08-23 06:30AM	Daily Vickers Top Insider Picks for 03/08/2023 (Argus Research)
Mar-07-23 06:34AM	Daily Vickers Top Insider Picks for 03/07/2023 (Argus Research)
Mar-06-23 07:22AM	Daily Vickers Top Insider Picks for 03/06/2023 (Argus Research) -5.13%
Mar-03-23 06:38AM	Daily Vickers Top Insider Picks for 03/03/2023 (Argus Research)
Mar-02-23 06:44AM	Daily Vickers Top Insider Picks for 03/02/2023 (Argus Research)
Mar-01-23 07:00AM	GlycoMimetics to Participate in Upcoming Cowen 43rd Annual Health Care Conference (Business Wire)
06:01AM	Daily Vickers Top Insider Picks for 03/01/2023 (Argus Research)
06:01AM	Daily Vickers Top Buyers & Sellers for 03/01/2023 (Argus Research)

Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Fairmount Funds Management LLC	Director	Dec 04 '25	Buy	13.41	1,360,000	18,237,600	2,747,866	Dec 08 04:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CBIO

Crescent Biopharma Inc

Upgrade your FINVIZ experience